Compare · COAG vs VRTX

COAG vs VRTX

Side-by-side comparison of Hemab Therapeutics Holdings Inc. (COAG) and Vertex Pharmaceuticals Incorporated (VRTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. COAG focuses on Biotechnology: Biological Products (No Diagnostic Substances), while VRTX focuses on Biotechnology: Pharmaceutical Preparations.
  • VRTX is the larger of the two at $130.58B, about 71.1x COAG ($1.84B).
  • VRTX has been more active in the news (12 items in the past 4 weeks vs 8 for COAG).
  • VRTX has more recent analyst coverage (25 ratings vs 0 for COAG).
MetricCOAGVRTX
Company
Hemab Therapeutics Holdings Inc.
Vertex Pharmaceuticals Incorporated
Price
-
-
Market cap
$1.84B
$130.58B
1M return
-
-3.79%
1Y return
-
+21.91%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2026
1991
News (4w)
8
12
Recent ratings
0
25
COAG

Hemab Therapeutics Holdings Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Hemab's mission is to discover, develop, and commercialize innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Hemab is building a franchise of innovative therapeutics designed to address critical gaps in the treatment of coagulation disorders, including sutacimig (HMB-001), a bispecific antibody in clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency, HMB-002, a monovalent antibody in clinical development for the prophylactic treatment of Von Willebrand Disease, and HMB-003, an antifibrinolytic targeting plasmin inhibition in clinical development for heavy menstrual bleeding.

VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest COAG

Latest VRTX